Legal and Regulatory Considerations The FDA has issued multiple warnings about compounded semaglutide products, clarifying that pharmacies may not legally compound medications that are essentially copies of commercially available, FDA-approved drugs unless a specific ingredient shortage exists
The regulatory landscape for compounding, particularly in the GLP-1 and peptide space, is transitioning from a period of limited oversight to one of heightened and highly visible enforcement activity
Why Switch From Semaglutide to Tirzepatide
The results of the phase 1 studies of AMG133 could provide insights into the role of GIP receptor antagonism within glucose metabolism, however, determining the exact effect of the GIP receptor antagonism remains challenging due to an anticipated influence of GLP-1 receptor agonism
Our 503A and 503B IV medications are tested for sterility, potency, and endotoxins, ensuring compliance with cGMP, USP , and FDA regulations
